Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Novel compounds synthesized at BMS particularly useful for prevention of postsurgical adhesions

Jan. 5, 1999

Allergan reports new compounds acting as retinoid antagonists or inverse agonists

Dec. 30, 1998

Aged garlic extract: in vitro and in vivo antiallergic effects

Dec. 28, 1998

FDA accepts Hyal's NDA for Solarase

Dec. 23, 1998

Suppression of chemokine production contributes to beneficial dermal effects of tacalcitol

Dec. 22, 1998

Maxim advances development of MaxDerm topical treatment

Dec. 22, 1998

Angiotech initiates another clinical trial with paclitaxel for treatment of psoriasis

Dec. 16, 1998

Antipruritic, immunosuppressive MS-444 derivatives reported by Kyowa Hakko

Dec. 15, 1998

Thalidomide evaluated for toxic epidermal necrolysis and found detrimental

Dec. 10, 1998

Abgenix initiates a phase I/II clinical trial in patients with psoriasis

Dec. 3, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...